The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; ipsen; Janssen-Cilag; Sanofi
Consulting or Advisory Role - Astellas Pharma; Bayer; Ferring; Janssen-Cilag; Sanofi
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Janssen-Cilag; Janssen-Cilag
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Multiple Companies as set out above
Addition of docetaxel to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Long-term survival, quality-adjusted survival, and cost-effectiveness analysis.
 
Nicholas James
Honoraria - Astellas Medivation; Bayer Health; Janssen; Merck Sharp & Dohme; Sanofi/Aventis
Consulting or Advisory Role - Astellas Medivation; Bayer; Janssen; Merck Sharp & Dohme; Roche; Sanofi/Aventis
Speakers' Bureau - Bayer; Ipsen; Janssen; Roche
Research Funding - Astellas Medivation (Inst); Bayer (Inst); Janssen (Inst); Roche (Inst); Sanofi/Aventis (Inst)
 
Beth Woods
No Relationships to Disclose
 
Eleftherios Sideris
No Relationships to Disclose
 
Melissa Ruth Spears
Research Funding - Astellas Pharma (Inst); Janssen (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
David P. Dearnaley
Honoraria - Janssen; Sandoz; Takeda
Consulting or Advisory Role - Cadence Research and Consulting; FirstWord; Janssen; Janssen Research & Development; Sandoz; Takeda
Speakers' Bureau - Janssen; Janssen-Cilag
Patents, Royalties, Other Intellectual Property - Abiraterone acetate was developed at The Institute of Cancer Research, which therefore has a commercial interest in the development of this agent. Professor Dearnaley is on the Institute’s Rewards to Inventors list for abiraterone acetate. (Inst)
Expert Testimony - Vitality Life
Travel, Accommodations, Expenses - Janssen; Takeda
 
Malcolm Mason
Research Funding - Sanofi (Inst)
 
Noel Clarke
No Relationships to Disclose
 
Mahesh K B Parmar
Research Funding - Sanofi (Inst)
 
Matthew Robert Sydes
Research Funding - Astellas Pharma; Clovis Oncology (Inst); Janssen-Cilag; Novartis; Pfizer; Sanofi
 
Mark Sculpher
No Relationships to Disclose